Skip to content

BIO-TECHNE Corp: net income or loss

BIO-TECHNE net income or loss: $73.4 million for the year ending 2025-06-30, down 56.3% on the year. 17 values since 2009, each linked to its SEC filing.

All BIO-TECHNE Corp financial histories

At a glance

BIO-TECHNE reported net income or loss of $73.4 million for the year ending 2025-06-30, down 56.3% from $168.1 million a year earlier. From 2009 to 2025 it fell at a compound 2.2% a year, from $105.2 million to $73.4 million. Across the last five reported years it ranged from $73.4 million (2025-06-30) to $285.3 million (2023-06-30). That was 6.0% of revenue ($1.22 billion) for the same year.

Computed from the values in the table below, in USD; each links to the filing it came from.

What this measure means

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Exact concept: us-gaap:NetIncomeLoss. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2008-07-01 to 2025-06-30. The SEC response was captured on 2026-09-19.

Selected filing history

Net income or loss in original reported units, latest-filed observation per period
Period startPeriod endValueUnitFiledSource filing
2024-07-012025-06-3073,400,000USD2025-08-2210-K · 0001558370-25-011716 SEC
2023-07-012024-06-30168,105,000USD2025-08-2210-K · 0001558370-25-011716 SEC
2022-07-012023-06-30285,263,000USD2025-08-2210-K · 0001558370-25-011716 SEC
2021-07-012022-06-30272,051,000USD2024-08-2210-K · 0001558370-24-012430 SEC
2020-07-012021-06-30140,410,000USD2023-08-2310-K · 0001558370-23-015226 SEC
2019-07-012020-06-30229,296,000USD2022-08-2410-K · 0001558370-22-013935 SEC
2018-07-012019-06-3096,072,000USD2021-08-2510-K · 0001437749-21-020980 SEC
2017-07-012018-06-30126,150,000USD2020-08-2610-K · 0001437749-20-018754 SEC
2016-07-012017-06-3076,086,000USD2019-11-0610-K/A · 0001437749-19-021760 SEC
2015-07-012016-06-30104,476,000USD2018-08-2710-K · 0001437749-18-016190 SEC
2014-07-012015-06-30107,735,000USD2017-09-0710-K · 0001437749-17-015711 SEC
2013-07-012014-06-30110,948,000USD2016-08-2910-K · 0001437749-16-038182 SEC
2012-07-012013-06-30112,561,000USD2015-08-3110-K · 0001437749-15-016645 SEC
2011-07-012012-06-30112,331,000USD2014-08-2910-K · 0001193125-14-327566 SEC
2010-07-012011-06-30112,302,000USD2013-08-2910-K · 0001193125-13-351961 SEC
2009-07-012010-06-30109,776,000USD2012-08-2910-K · 0001193125-12-373084 SEC
2008-07-012009-06-30105,242,000USD2011-08-2910-K · 0001193125-11-235045 SEC

Related BIO-TECHNE Corp histories

All 61 BIO-TECHNE histories

Inspect the source

Entity
BIO-TECHNE Corp / CIK 0000842023
Captured
SEC response SHA-256
5f064cd631289049236c7ddafd76f1bc2824b0b55936587bf5e0bb2cc7a0f677

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

The MCP server is free and MIT-licensed: npx -y canli-mcp. If these records help your research, a star on GitHub helps other researchers find them.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000842023.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))